#United States #Overland Park #Canine Health #Dechra #CosACTHen

Dechra's CosACTHen®: A New Era in Canine Endocrinology

Dechra Pharmaceuticals is thrilled to announce the recent approval of CosACTHen®, an innovative cosyntropin injection, as sanctioned by the U.S. Food and Drug Administration (FDA). This pivotal development positions CosACTHen® as the first and only cosyntropin tailored specifically for canine patients, marking a significant milestone in veterinary endocrinology.

Advancing Canine Health

As most pet owners know, diagnosing issues related to endocrine function can be challenging. CosACTHen® is an essential tool for veterinarians, enhancing their capability to evaluate adrenal function in dogs. This approval is particularly noteworthy for practitioners dealing with conditions such as Cushing's Disease and Addison's Disease, which have become increasingly prevalent in canine populations.

CosACTHen® is integral to ACTH stimulation testing, the primary method used to confirm these serious conditions. By providing precise evaluations of adrenocortical function, it enables veterinarians to make informed decisions about treatment plans, ultimately ensuring better health outcomes for their canine patients.

Features of CosACTHen®

• - Indication: Designed specifically for the evaluation of adrenal function in dogs.
• - Product Details: Available as a 0.25 mg/ml solution in single-use vials (1 ml each), allowing for easy administration.
• - Dosing Information: It can be administered either via intravenous or intramuscular injection, making it a versatile option for various clinical settings.
• - Storage Recommendations: CosACTHen® should be kept refrigerated to ensure its efficacy, allowing for quick access in urgent cases.

In the words of Dr. Jill Stohs, Sr. Director of Veterinary Professional Services and Medical Affairs at Dechra, "With CosACTHen®, veterinarians can confidently perform ACTH stimulation tests, translating to reassurance for pet parents knowing their dog’s diagnosis and monitoring are up-to-date with the latest advancements in endocrine care."

Commitment to Excellence

Dechra's commitment extends beyond just the introduction of CosACTHen®. With more than 1,200 case consults dedicated to Cushing's Disease over the last year, Dechra has reaffirmed its position as a leader in veterinary specialty care and endocrinology. The company's Veterinary Technical Services team is available to support veterinarians with resources that promote best practices in diagnostics and patient management.

Important Safety Information

While CosACTHen® presents valuable opportunities in canine health management, it is essential for veterinarians and pet owners to be aware of potential side effects. The product must be administered only to dogs, and previous hypersensitivity reactions to cosyntropin must be considered before use. Reported adverse events include lethargy, anxiety, muscle tremors, and other gastrointestinal issues, highlighting the importance of comprehensive monitoring during treatment.

CosACTHen® is not intended for human use, and precautions should be taken to avoid accidental self-injection, particularly among pregnant or breastfeeding women.

About Dechra

Dechra is recognized globally as a specialized veterinary pharmaceutical company dedicated to advancing the health and well-being of animals. Their products, like CosACTHen® and Vetoryl® Capsules, showcase their commitment to innovative veterinary care.

To learn more about the latest advancements from Dechra, please visit www.dechra-us.com. With this latest approval, Dechra continues to solidify its role as a trusted partner in enhancing veterinary care and the health of canine companions.